Skip to main content
. 2016 Oct 12;12(6):4312–4318. doi: 10.3892/ol.2016.5246

Table III.

Adverse effects exhibited in giant cell tumor of bone patients following treatment with denosumab.

Adverse effect Grade II toxicity, n (%) Grade III toxicity, n (%)
Hypophosphatemia 8 (23) 1 (3)
Hypocalcemia   3 (9) 1 (3)

No grade IV toxicity was observed.